Related Experiment Video
Updated: Aug 23, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth
Kenneth M Petersen1, Lisa R Bulkow, Brian J McMahon
1Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Alaska Native Tribal Health Consortium, Anchorage, AK 99508, USA.
Insights
Hepatitis B vaccine protection wanes by 5 years in most infants. While many children retain immune memory, some require booster doses. Further research is needed to determine optimal hepatitis B booster timing.
Area of Science:
- Immunology
- Pediatrics
- Vaccinology
Background:
- The long-term protective immunity conferred by infant hepatitis B vaccination remains undetermined.
- Infant hepatitis B vaccination is a standard public health intervention.
- Understanding vaccine durability is crucial for public health policy.
Purpose of the Study:
- To assess the duration of antibody protection against hepatitis B virus in children vaccinated from birth.
- To evaluate the immunologic memory and response to booster doses in children with waning immunity.
- To inform recommendations regarding hepatitis B booster vaccination schedules.
Main Methods:
- Longitudinal follow-up of 363 low-risk children vaccinated at birth with hepatitis B vaccine.
- Measurement of antibody to hepatitis B surface antigen (anti-HBs) titers at various ages (4-13 years).
- Administration of booster doses to participants with nonprotective anti-HBs titers (<10 mIU/mL).
Main Results:
- Anti-HBs titers declined below protective levels by 5-7 years in most children receiving recombinant vaccine, and by 9-13 years for plasma-derived vaccine.
- A significant proportion of children with nonprotective titers responded robustly to a booster dose (61-91%).
- Children born to hepatitis B surface antigen (HBsAg)-positive mothers showed similar waning immunity but a high response rate to boosters.
Conclusions:
- Antibody protection from infant hepatitis B vaccination diminishes significantly within 5-13 years.
- Most children demonstrate immunologic memory, but a notable fraction requires booster doses.
- Further long-term studies are essential to establish the necessity and optimal timing for hepatitis B booster vaccinations.
Background:
The duration of protection after hepatitis B vaccination of infants is unknown.
Methods:
We determined antibody to hepatitis B surface antigen (anti-HBs) at 4-13 years of age in 363 low risk children who had been vaccinated starting at birth with hepatitis B vaccine. Those with nonprotective titers (<10 mIU/mL) received a booster dose. We similarly followed 16 children of hepatitis B surface antigen (HBsAg)-positive mothers.
Results:
Of low risk infants receiving a plasma-derived vaccine, 41% (42 of 102) of those whose primary response was unknown and 24% (4 of 17) who had initially responded retained protective titers (> or = 10 mIU/mL) of anti-HBs at 9 and 13 years, respectively. Of those who did not have protective antibody titers, 61% (33 of 54) and 67% (8 of 12), respectively, responded to a booster dose. In children of HBsAg-positive mothers, 31% retained protective anti-HBs at 12 years, and 90% (9 of 10) with nonprotective titers responded to a booster. In low risk children initially receiving a recombinant vaccine, 12.5% (26 of 208) and none (0 of 36) retained protective anti-HBs titers at 5 and 7 years of age, respectively. Of those who did not have protective titers, 90% (120 of 134) and 91% (32 of 35), respectively, responded to a booster.
Conclusions:
Anti-HBs disappeared by 5 years of age in most children who were vaccinated with hepatitis B vaccine from birth. Although most children showed immunologic memory, one-third failed to demonstrate an anamnestic response to a booster dose. Additional long term studies of low risk infants are needed to determine duration of protection and the necessity for or timing of booster doses.
Related Concept Videos
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...
Vaccinations
Vaccines
Hepatitis
Active versus Passive Immunity
Active Immunity
Active immunity refers to the resistance one develops...
